insulin secretion, shown in two of our patients, is one contributing factor. In addition we have evidence that, during diazoxide therapy, peripheral glucose utilization was impaired by an intracellular block in glucose metabolism, because diazoxide not only slowed the rate of glucose disappearance but also increased the volume of distribution of glucose. While there is some evidence that diazoxide may increase hepatic glucose release, the elevation of the fasting blood sugar in glycogen storage disease (debranching enzyme deficiency) showed that diazoxide is effective even when hepatic glycogenolysis is severely impaired. Other studies have implied that high doses of potassium or f-adrenergic blocking agents will diminish the hyperglycmmic effect of diazoxide in normal man or animals (Staquet et al. 1965 ).
Summary
Diazoxide is an experimental drug of value in the treatment of intractable hypoglycemia but more long term experience is required to define its place in therapy. However, its place in the management of hypoglycemia due to malignant insulinoma and non-islet cell tumours is established (Marks & Samols 1966) . There is sufficient evidence that in infants with different types of idiopathic hypoglycemia the advantages of diazoxide outweigh its mild side effects. Brief trials of diazoxide in glycogen storage disease were surprisingly encouraging. We conclude that diazoxide therapy should be considered in the management of all cases of severe recurrent fasting hypoglycwmia when the cause is not amenable to other treatment. Tyrosinosis was first described by Medes (1932) . A 49-year-old man with myasthenia gravis appeared to lack the enzyme p-hydroxyphenylpyruvate hydroxylase and, in consequence, excreted in his urine large amounts ofp-hydroxyphenylpyruvic acid (p-HPPA) and the related substances tyrosine and p-hydroxyphenyl-lactic acid (p-HPLA). Over the past fifteen years it has become apparent that a similar enzymic defect occurs in some children who present with hepatic and renal tubular dysfunction.
Of the seven patients investigated by the author, one (first seen in 1950) presents the 'typical' clinical and biochemical picture. At 2 years 3 months this girl presented with rickets that did not respond to vitamin D and very marked hepatomegaly (first noted at the age of 10 months). There was severe and intractable renal acidosis, gross generalized aminoaciduria, glucosuria, fructosuria and moderate proteinuria. The child's urine consistently contained tyrosine, p-HPPA, p-HPLA and related phenolic acids in very large amounts, suggesting absence or inactivity of p-hydroxyphenylpyruvate hydroxylase. The child died at the age of 7 years 3 months and, at necropsy, multilobular hepatic cirrhosis was found. The term 'congenital hepatic and renal dysfunction' was coined for this condition (Woolf 1961 (Woolf , 1962 (Woolf , 1963 and later changed to 'inborn hepato-renal dysfunction' (Woolf 1966 (1964), Halvorsen & Gjessing (1964) , Gentz et al. (1965) and Tanagushi & Gjessing (1965) . Most of these patients died before puberty.
Of the other 6 patients investigated by the author, 5 presented withjaundice and an enlarging liver within a few days or weeks of birth; the sixth failed to gain weight or feed satisfactorily, had a bleeding tendency, was found to have a prothrombin level only 16% to 23% of normal and had an enlarging liver. Five of these 6 children died aged, respectively, 1 week, 3i, 71, 101 and 13 weeks. All showed evidence of renal tubular failure to reabsorb aminoacids and/or glucose; where they were looked for, tyrosine, p-HPPA and p-HPLA were found in the urine in large amounts. The remaining patient presented with rapidly deepening jaundice twenty-four hours after birth; he remained jaundiced till 4 months of age. However, he survived with cirrhosis of the liver and eventually died in hepatic coma aged 13j years. For two years before his death he had azotwmia, hypertension and 'trace' proteinuria, but his urine was not examined further. At the age of 71 years there was no evidence of renal tubular dysfunction.
Zetterstrom (1963) refers to patients aged up to 19 years. One, at least, is now aged 23 years and is clinically well (Gentz 1966) . One of the patients of Fritzell et al. (1964) appeared to have recovered by the age of 5 years 8 months. The condition is protean in its clinical manifestations and recognition of a single entity would have been impossible but for its familial nature. In several instances two siblings have been affected, one dying in early infancy with the fulminating hepatic form of the disease, the other surviving into childhood or adult life with, typically, cirrhosis, vitamin D resistant rickets, acidosis and multiple renal tubular dysfunctions, though some of these features were sometimes absent. All cases appeared to have a block in the metabolism of tyrosine suggesting partial or complete absence or inactivity of p-hydroxyphenylpyruvate hydroxylase, at least at times. It seems probable that all the cases described were of the same condition and Medes's patient may well have had this condition too, hence 'tyrosinosis' is an appropriate name.
The occurrence in siblings but not in parents, and Zetterstrom's geographical data, suggest that the disease is determined by a single pair of autosomal genes. Presumably the mutant gene fails to synthesize an enzyme or other macromolecule, by analogy with other inborn errors of metabolism. It has been suggested that the primary gene product concerned is p-hydroxyphenylpyruvate hydroxylase itself and that the clinical features result from an intoxication by the p-HPPA that accumulates. This seems unlikely; p-HPPA is without any detectable clinical effect in the many neonates who, as a transient phenomenon, lack p-hydroxyphenylpyruvate hydroxylase for a few weeks after birth, and there is no effect on renal tubular reabsorption of amino acids and sugars in these infants (Bloxam et al. 1960 , Goodwin 1964 ). In addition, those patients with tyrosinosis who have only a partial or intermittent lack of the enzyme must possess the gene coded for the enzyme. It seems more likely that the mutant gene causes the accumulation of some unidentified metabolite with a toxic action on the liver and the renal tubules and that the enzyme p-hydroxyphenylpyruvate hydroxylase is secondarily inhibited.
Treatment of the older children is by administration of bicarbonate or citrate for acidosis, potassium salts for hypokalbmia, large doses of vitamin D and/or phosphate for rickets, i.e. replacement therapy which may be effective in prolonging life. Recently a diet low in phenylalanine and tyrosine has been used in three patients, aged 1 year or more, with the clinical and biochemical features of tyrosinosis, including hypophosphatwmic rickets, acidosis, hepatomegaly, hypotonia, and generalized aminoaciduria with tyrosine predominating. The results were very encouraging: the net renal tubular reabsorption of phosphate rose, e.g. from 7% to 96%, the serum phosphate concentration rose and the rickets healed, and urinary aminoacid excretion dropped to normal (Halvorsen & Gjessing 1964 , 1966 , Palmgren 1966 and personal communication, Jagenburg 1965 . In the absence of any effective treatment for the fulminating hepatic form of the disease seen in early infancy, it would seem worth trying a diet low in phenylalanine and tyrosine; such a diet has been prepared on an experimental basis by one firm. To be effective this diet should presumably be given very early -irreversible damage to the liver seems to occur within a few weeks, or sometimes even days, of birth. It may also be worth investigating promethazine, an antihistamine drug that greatly reduces the hepatotoxic effects of, e.g., carbon tetrachloride. Any treatment that helped tide the infant over the first few months might have a considerable effect on the prognosis.
